3245.0: Monday, November 13, 2000: 8:30 PM-10:00 PM | ||||
| ||||
| Primary Organizer: Katherine S. Virgo, Ph.D., Department of Surgery, St. Louis University Health Sciences Center/Department of Veterans Affairs Medical Center, 3635 Vista at Grand Blvd, St. Louis, MO 63110-0250; E-mail: virgoks@slu.edu; Phone: (314) 289-7023; Fax: (314) 289-7038 Secondary Organizer: Frank E. Johnson, M.D., Same affiliations as above Section: Epidemiology Overview: The proposed session will examine and compare predictors of variation in the follow-up of patients after treatment with curative intent for several different cancers. The session will also analyze the costs associated with variation in surveillance methodologies. Many groups have issued guidelines for cancer patient follow-up. The evidence backing these recommendations is often lacking. Confusion and ambiguity pervade the literature, in large part as a result of the absence of properly controlled trials comparing the costs and benefits of the various surveillance strategies advocated. Analyses of variation in cancer patient surveillance and associated costs is a topic especially relevant to this year’s APHA Annual Meeting theme, “Eliminating Health Disparities.” Studies of current practice patterns for various cancer sites suggest wide disparities which generally are not well explained by physician age, tumor stage, or factors believed to motivate physicians in decision making. This session will specifically discuss colorectal, lung, prostate, and renal carcinoma as well as melanoma | ||||
| See individual abstracts for presenting author's disclosure statement. | ||||
| Learning Objectives: Refer to the individual abstracts for learning objectives | ||||
| Angela D. Booth-Jones, MS Marlene Goldman, ScD | ||||
| Cancer patient follow-up costs posttreatment Katherine S. Virgo, PhD, MBA | ||||
| Contemporary management of renal cell carcinoma Paul Russo, MD | ||||
| Prostate cancer prevalence estimates in the United States Ray M. Merrill, PhD, MPH | ||||
| Surveillance of melanoma patients after potentially curative treatment Frank E. Johnson, MD, Barry S. Handler, MD, David Y. Johnson, Kay Goshima, MD | ||||
| Sponsor: | Epidemiology | |||
| Cosponsors: | Medical Care | |||